Viewing Opinion | StockChase

Bristol Myers Squibb (BMY-N) opinion on 2017-08-10

Last Price Recorded: 63.4700 on 2017-12-13

ON STOCKCHASE SINCE Apr 2001

biotechnology/pharmaceutical
biotechnology/pharmaceutical
TOP PICK

Robert Lauzon
Bristol Myers Squibb was $56.590 at time of opinion
Owned : Yes

It represents tremendous value for patient investors.  Over 3-4 years there is tremendous value in the pipeline of drugs.  They have the best franchise.  There are activists involved.  It could be an M&A target.  (Analysts’ target: $58.00).

CAUTIOUS

All opinions for BMY-N (131)

27 BUY
21 COMMENT
30 DON'T BUY
7 HOLD
2 PARTIAL SELL
12 PAST TOP PICK
3 SELL
1 SELL ON STRENGTH
22 TOP PICK
3 WATCH
3 WEAK BUY
View All

More experts covering BMY-N

SAVE
Add BMY-N to Watch List

All opinions for BMY-N (131)

27 BUY
21 COMMENT
30 DON'T BUY
7 HOLD
2 PARTIAL SELL
12 PAST TOP PICK
3 SELL
1 SELL ON STRENGTH
22 TOP PICK
3 WATCH
3 WEAK BUY
View All

More experts covering BMY-N

SAVE
Add BMY-N to Watch List

Last 60 Days Opinions

PAST TOP PICK
1 month ago

No Comments.


You must be logged in to comment.

Successfully Saved Company